Patricia J. Schäfenacker , Stefanie Hecker-Nolting , Stefan Bielack , Matthias Kevric , Benjamin Sorg , Arndt Borkhardt , Bernd Hertenstein , Peter Reichardt , Daniel A. Müller , Leo Kager , Mathias Werner , Claudia Blattmann
{"title":"High-grade surface Osteosarcoma – Data from the Cooperative Osteosarcoma Study Group (COSS)","authors":"Patricia J. Schäfenacker , Stefanie Hecker-Nolting , Stefan Bielack , Matthias Kevric , Benjamin Sorg , Arndt Borkhardt , Bernd Hertenstein , Peter Reichardt , Daniel A. Müller , Leo Kager , Mathias Werner , Claudia Blattmann","doi":"10.1016/j.phoj.2026.100809","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>High-grade surface osteosarcoma (HGSOS) is a rare subtype of osteosarcoma, accounting for approximately 1% of all cases. Due to its rarity, data on clinical characteristics, treatment, and outcomes remain limited.</div></div><div><h3>Methods</h3><div>Patients with a histologically confirmed diagnosis of HGSOS registered in the Cooperative Osteosarcoma Study Group (COSS) between 1978 and 2021 were retrospectively analyzed. Event-free survival (EFS) and overall survival rate (OAS) were estimated using Kaplan–Meier analysis, and potential prognostic factors were explored.</div></div><div><h3>Results</h3><div>Thirty-one patients met the inclusion criteria. Median age at diagnosis was 16.8 years, and tumors were predominantly located in the extremities (83.9%). Primary metastatic disease at diagnosis was rare (n = 1). At a median follow-up of 5.33 years, 3- and 5-year EFS were 79.5% and 75.3%, while 3- and 5-year OAS were 82.7% and 78.1%, respectively. Larger tumor volume, poor histological response to neoadjuvant chemotherapy, and early recurrence were associated with inferior outcomes in univariate analyses. In multivariate analysis, tumor localization in an extremity was identified as the only independent predictor of overall survival.</div></div><div><h3>Conclusions</h3><div>Patients with HGSOS treated within multimodal osteosarcoma protocols demonstrated favorable survival outcomes. Prognostic interpretation is limited by the small cohort size; however, tumor localization, tumor volume, histological response, and timing of recurrence appear to influence outcome. Larger collaborative studies are needed to further define prognostic factors in this rare tumor entity.</div></div>","PeriodicalId":101004,"journal":{"name":"Pediatric Hematology Oncology Journal","volume":"11 1","pages":"Article 100809"},"PeriodicalIF":0.0000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Hematology Oncology Journal","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468124526000070","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/6 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background
High-grade surface osteosarcoma (HGSOS) is a rare subtype of osteosarcoma, accounting for approximately 1% of all cases. Due to its rarity, data on clinical characteristics, treatment, and outcomes remain limited.
Methods
Patients with a histologically confirmed diagnosis of HGSOS registered in the Cooperative Osteosarcoma Study Group (COSS) between 1978 and 2021 were retrospectively analyzed. Event-free survival (EFS) and overall survival rate (OAS) were estimated using Kaplan–Meier analysis, and potential prognostic factors were explored.
Results
Thirty-one patients met the inclusion criteria. Median age at diagnosis was 16.8 years, and tumors were predominantly located in the extremities (83.9%). Primary metastatic disease at diagnosis was rare (n = 1). At a median follow-up of 5.33 years, 3- and 5-year EFS were 79.5% and 75.3%, while 3- and 5-year OAS were 82.7% and 78.1%, respectively. Larger tumor volume, poor histological response to neoadjuvant chemotherapy, and early recurrence were associated with inferior outcomes in univariate analyses. In multivariate analysis, tumor localization in an extremity was identified as the only independent predictor of overall survival.
Conclusions
Patients with HGSOS treated within multimodal osteosarcoma protocols demonstrated favorable survival outcomes. Prognostic interpretation is limited by the small cohort size; however, tumor localization, tumor volume, histological response, and timing of recurrence appear to influence outcome. Larger collaborative studies are needed to further define prognostic factors in this rare tumor entity.